Dalbavancin (INN, trade name Dalvance) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin.The Food and Drug Administration approved dalbavancin for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria.